Cargando…

Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions

OBJECTIVE: To identify the diagnostic ability of precontrast and contrast-enhanced ultrasound (CEUS) in differentiating between malignant and benign solid pancreatic lesions (MSPLs and BSPLs) and to develop an easy-to-use diagnostic nomogram. MATERIALS AND METHODS: This study was approved by the ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jiayan, Yang, Jie, Ding, Jianming, Zhou, Jing, Yang, Rui, Li, Jiawu, Luo, Yan, Lu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705429/
https://www.ncbi.nlm.nih.gov/pubmed/35751698
http://dx.doi.org/10.1007/s00330-022-08930-0
_version_ 1784840282012909568
author Huang, Jiayan
Yang, Jie
Ding, Jianming
Zhou, Jing
Yang, Rui
Li, Jiawu
Luo, Yan
Lu, Qiang
author_facet Huang, Jiayan
Yang, Jie
Ding, Jianming
Zhou, Jing
Yang, Rui
Li, Jiawu
Luo, Yan
Lu, Qiang
author_sort Huang, Jiayan
collection PubMed
description OBJECTIVE: To identify the diagnostic ability of precontrast and contrast-enhanced ultrasound (CEUS) in differentiating between malignant and benign solid pancreatic lesions (MSPLs and BSPLs) and to develop an easy-to-use diagnostic nomogram. MATERIALS AND METHODS: This study was approved by the institutional review board. Patients with pathologically confirmed solid pancreatic lesions were enrolled from one tertiary medical centre from March 2011 to June 2021 and in two tertiary institutions between January 2015 and June 2021. A prediction nomogram model was established in the training set by using precontrast US and CEUS imaging features that were independently associated with MSPLs. The performance of the prediction model was further externally validated. RESULTS: A total of 155 patients (mean age, 55 ± 14.6 years, M/F = 84/71) and 78 patients (mean age, 59 ± 13.4 years, M/F = 36/42) were included in the training and validation cohorts, respectively. In the training set, an ill-defined border and dilated main pancreatic duct on precontrast ultrasound, CEUS patterns of hypoenhancement in both the arterial and venous phases of CEUS, and hyperenhancement/isoenhancement followed by washout were independently associated with MSPLs. The prediction nomogram model developed with the aforementioned variables showed good performance in differentiating MSPLs from BSPLs with an area under the curve (AUC) of 0.938 in the training set and 0.906 in the validation set. CONCLUSION: Hypoenhancement in all phases, hyperenhancement/isoenhancement followed by washout on CEUS, an ill-defined border, and a dilated main pancreatic duct were independent risk factors for MSPLs. The nomogram constructed based on these predictors can be used to diagnose MSPLs. KEY POINTS: • An ill-defined border and dilated main pancreatic duct on precontrast ultrasound, hypoenhancement in all phases of CEUS, and hyperenhancement/isoenhancement followed by washout were independently associated with MSPLs. • The ultrasound-based prediction model showed good performance in differentiating MSPLs from BSPLs with an AUC of 0.938 in the training set and 0.906 in the external validation set. • An ultrasound-based nomogram is an easy-to-use tool to differentiate between MSPLs and BSPLs with high efficacy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-08930-0.
format Online
Article
Text
id pubmed-9705429
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97054292022-11-30 Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions Huang, Jiayan Yang, Jie Ding, Jianming Zhou, Jing Yang, Rui Li, Jiawu Luo, Yan Lu, Qiang Eur Radiol Gastrointestinal OBJECTIVE: To identify the diagnostic ability of precontrast and contrast-enhanced ultrasound (CEUS) in differentiating between malignant and benign solid pancreatic lesions (MSPLs and BSPLs) and to develop an easy-to-use diagnostic nomogram. MATERIALS AND METHODS: This study was approved by the institutional review board. Patients with pathologically confirmed solid pancreatic lesions were enrolled from one tertiary medical centre from March 2011 to June 2021 and in two tertiary institutions between January 2015 and June 2021. A prediction nomogram model was established in the training set by using precontrast US and CEUS imaging features that were independently associated with MSPLs. The performance of the prediction model was further externally validated. RESULTS: A total of 155 patients (mean age, 55 ± 14.6 years, M/F = 84/71) and 78 patients (mean age, 59 ± 13.4 years, M/F = 36/42) were included in the training and validation cohorts, respectively. In the training set, an ill-defined border and dilated main pancreatic duct on precontrast ultrasound, CEUS patterns of hypoenhancement in both the arterial and venous phases of CEUS, and hyperenhancement/isoenhancement followed by washout were independently associated with MSPLs. The prediction nomogram model developed with the aforementioned variables showed good performance in differentiating MSPLs from BSPLs with an area under the curve (AUC) of 0.938 in the training set and 0.906 in the validation set. CONCLUSION: Hypoenhancement in all phases, hyperenhancement/isoenhancement followed by washout on CEUS, an ill-defined border, and a dilated main pancreatic duct were independent risk factors for MSPLs. The nomogram constructed based on these predictors can be used to diagnose MSPLs. KEY POINTS: • An ill-defined border and dilated main pancreatic duct on precontrast ultrasound, hypoenhancement in all phases of CEUS, and hyperenhancement/isoenhancement followed by washout were independently associated with MSPLs. • The ultrasound-based prediction model showed good performance in differentiating MSPLs from BSPLs with an AUC of 0.938 in the training set and 0.906 in the external validation set. • An ultrasound-based nomogram is an easy-to-use tool to differentiate between MSPLs and BSPLs with high efficacy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-08930-0. Springer Berlin Heidelberg 2022-06-25 2022 /pmc/articles/PMC9705429/ /pubmed/35751698 http://dx.doi.org/10.1007/s00330-022-08930-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gastrointestinal
Huang, Jiayan
Yang, Jie
Ding, Jianming
Zhou, Jing
Yang, Rui
Li, Jiawu
Luo, Yan
Lu, Qiang
Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
title Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
title_full Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
title_fullStr Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
title_full_unstemmed Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
title_short Development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
title_sort development and validation of an ultrasound-based prediction model for differentiating between malignant and benign solid pancreatic lesions
topic Gastrointestinal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705429/
https://www.ncbi.nlm.nih.gov/pubmed/35751698
http://dx.doi.org/10.1007/s00330-022-08930-0
work_keys_str_mv AT huangjiayan developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT yangjie developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT dingjianming developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT zhoujing developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT yangrui developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT lijiawu developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT luoyan developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions
AT luqiang developmentandvalidationofanultrasoundbasedpredictionmodelfordifferentiatingbetweenmalignantandbenignsolidpancreaticlesions